Chemoprevention of colorectal cancer by targeting obesity-related metabolic abnormalities

World Journal of Gastroenterology

Volumn , Issue 27, 2014, Pages 8939-8946

  Shirakami, Yohei ^a   Shimizu, Masahito ^a   Kubota, Masaya ^a   Araki, Hiroshi ^a   Tanaka, Takuji ^a   Moriwaki, Hisataka ^a   Seishima, Mitsuru ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Branched chain amino acid; Chemoprevention; Colorectal cancer; Green tea catechin; Obesity

Indexed keywords

AZOXYMETHANE; BETA CATENIN; CAPTOPRIL; CATECHIN; EPIGALLOCATECHIN GALLATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; PITAVASTATIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TELMISARTAN; TUMOR NECROSIS FACTOR ALPHA; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT;

CARCINOGENESIS; CHEMOPROPHYLAXIS; CHRONIC INFLAMMATION; COLORECTAL CANCER; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LIPID OXIDATION; METABOLIC DISORDER; NUTRITIONAL ASSESSMENT; OBESITY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ADVERSE EFFECTS; ANIMAL; CELL TRANSFORMATION; COLORECTAL NEOPLASMS; COMPLICATION; DIET; DIET SUPPLEMENTATION; DRUG EFFECTS; METABOLISM; NUTRITIONAL STATUS; RISK FACTOR; RISK REDUCTION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; ANTIHYPERTENSIVE AGENTS; CATECHIN; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DIET; DIETARY SUPPLEMENTS; HUMANS; HYPOLIPIDEMIC AGENTS; NUTRITIONAL STATUS; OBESITY; RISK FACTORS; RISK REDUCTION BEHAVIOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84905386157     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i27.8939     Document Type: Review

References (81)

1. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011; 11: 886-895 [PMID: 22113164 DOI: 10.1038/nrc3174]
2. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-1638 [PMID: 12711737 DOI: 10.1056/NEJMoa021423]
3. Aleksandrova K, Nimptsch K, Pischon T. Obesity and colorectal cancer. Front Biosci (Elite Ed) 2013; 5: 61-77 [PMID: 23276970]
4. Anderson AS, Caswell S. Obesity management - an opportunity for cancer prevention. Surgeon 2009; 7: 282-285 [PMID: 19848061]
5. Frezza EE, Wachtel MS, Chiriva-Internati M. Influence of obesity on the risk of developing colon cancer. Gut 2006; 55: 285-291 [PMID: 16239255]
6. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007; 132: 2208-2225 [PMID: 17498513]
7. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578 [PMID: 18280327 DOI: 10.1016/S0140-6736(08)60269-X]
8. Ramos-Nino ME. The role of chronic inflammation in obesity-associated cancers. ISRN Oncol 2013; 2013: 697521 [PMID: 23819063 DOI: 10.1155/2013/697521]
9. Yasuda Y, Shimizu M, Shirakami Y, Sakai H, Kubota M, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H. Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Cancer Sci 2010; 101: 1701-1707 [PMID: 20398056 DOI: 10.1111/j.1349-7006.2010.01579.x]
10. Kubota M, Shimizu M, Sakai H, Yasuda Y, Ohno T, Kochi T, Tsurumi H, Tanaka T, Moriwaki H. Renin-angiotensin system inhibitors suppress azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Biochem Biophys Res Commun 2011; 410: 108-113 [PMID: 21640075 DOI: 10.1016/j.bbrc.2011.05.115]
11. Kao YH, Chang HH, Lee MJ, Chen CL. Tea, obesity, and diabetes. Mol Nutr Food Res 2006; 50: 188-210 [PMID: 16416476 DOI: 10.1002/mnfr.200500109]
12. Shimizu M, Adachi S, Masuda M, Kozawa O, Moriwaki H. Cancer chemoprevention with green tea catechins by targeting receptor tyrosine kinases. Mol Nutr Food Res 2011; 55: 832-843 [PMID: 21538846 DOI: 10.1002/mnfr.201000622]
13. Shimizu M, Shirakami Y, Moriwaki H. Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG. Int J Mol Sci 2008; 9: 1034-1049 [PMID: 19325845 DOI: 10.3390/ijms9061034]
14. Shimizu M, Weinstein IB. Modulation of signal transduction by tea catechins and related phytochemicals. Mutat Res 2005; 591: 147-160 [PMID: 15992833]
15. Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 2009; 9: 429-439 [PMID: 19472429 DOI: 10.1038/nrc2641]
16. Kubota M, Shimizu M, Sakai H, Yasuda Y, Terakura D, Baba A, Ohno T, Tsurumi H, Tanaka T, Moriwaki H. Preventive effects of curcumin on the development of azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db obese mice. Nutr Cancer 2012; 64: 72-79 [PMID: 22172229 DOI: 10.1080/01635581.2012.630554]
17. Kawaguchi T, Nagao Y, Matsuoka H, Ide T, Sata M. Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Int J Mol Med 2008; 22: 105-112 [PMID: 18575782]
18. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, Rossi Fanelli F, Abbiati R. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 2003; 124: 1792-1801 [PMID: 12806613]
19. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, Kato M, Nakamura T, Higuchi K, Nishiguchi S, Kumada H. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005; 3: 705-713 [PMID: 16206505]
20. Shimizu M, Shirakami Y, Iwasa J, Shiraki M, Yasuda Y, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H. Supplementation with branched-chain amino acids inhibits azoxymethane-induced colonic preneoplastic lesions in male C57BL/KsJ-db/db mice. Clin Cancer Res 2009; 15: 3068-3075 [PMID: 19366832 DOI: 10.1158/1078-0432.CCR-08-2093]
21. Chang CK, Ulrich CM. Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia 2003; 46: 595-607 [PMID: 12764580 DOI: 10.1007/s00125-003-1109-5]
22. Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol 2011; 7: 11-24 [PMID: 20956999 DOI: 10.1038/nrendo.2010.171]
23. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928 [PMID: 19029956 DOI: 10.1038/nrc2536]
24. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001; 131: 3109S-3120S [PMID: 11694656]
25. Björk J, Nilsson J, Hultcrantz R, Johansson C. Growth-regulatory effects of sensory neuropeptides, epidermal growth factor, insulin, and somatostatin on the non-transformed intestinal epithelial cell line IEC-6 and the colon cancer cell line HT 29. Scand J Gastroenterol 1993; 28: 879-884 [PMID: 7505479]
26. Tran TT, Medline A, Bruce WR. Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev 1996; 5: 1013-1015 [PMID: 8959325]
27. Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 2004; 68: 1003-1015 [PMID: 15313394 DOI: 10.1016/j.bcp.2004.05.029]
28. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002; 94: 972-980 [PMID: 12096082]
29. Durai R, Yang W, Gupta S, Seifalian AM, Winslet MC. The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis 2005; 20: 203-220 [PMID: 15650828 DOI: 10.1007/s00384-004-0675-4]
30. Singh P, Rubin N. Insulinlike growth factors and binding proteins in colon cancer. Gastroenterology 1993; 105: 1218-1237 [PMID: 7691674]
31. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-2072 [PMID: 12379575]
32. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996; 271: 665-668 [PMID: 8571133]
33. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745-E751 [PMID: 11287357]
34. Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006; 42: 745-750 [PMID: 16517151]
35. Flores MB, Rocha GZ, Damas-Souza DM, Osório-Costa F, Dias MM, Ropelle ER, Camargo JA, de Carvalho RB, Carvalho HF, Saad MJ, Carvalheira JB. Obesity-induced increase in tumor necrosis factor-α leads to development of colon cancer in mice. Gastroenterology 2012; 143: 741-753.e1-4 [PMID: 22677195 DOI: 10.1053/j.gastro.2012.05.045]
36. Leslie NR. The redox regulation of PI 3-kinase-dependent signaling. Antioxid Redox Signal 2006; 8: 1765-1774 [PMID: 16987030 DOI: 10.1089/ars.2006.8.1765]
37. Valko M, Izakovic M, Mazur M, Rhodes CJ, Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 2004; 266: 37-56 [PMID: 15646026]
38. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 2007; 86: s858-s866 [PMID: 18265479]
39. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295 [PMID: 8532024 DOI: 10.1056/NEJM199602013340503]
40. Fenton JI, Hursting SD, Perkins SN, Hord NG. Interleukin-6 production induced by leptin treatment promotes cell proliferation in an Apc (Min/+) colon epithelial cell line. Carcinogenesis 2006; 27: 1507-1515 [PMID: 16597643]
41. Molina A, Vendrell J, Gutiérrez C, Simón I, Masdevall C, Soler J, Gómez JM. Insulin resistance, leptin and TNF-alpha system in morbidly obese women after gastric bypass. Obes Surg 2003; 13: 615-621 [PMID: 12935365 DOI: 10.1381/096089203322190844]
42. Amemori S, Ootani A, Aoki S, Fujise T, Shimoda R, Kakimoto T, Shiraishi R, Sakata Y, Tsunada S, Iwakiri R, Fujimoto K. Adipocytes and preadipocytes promote the proliferation of colon cancer cells in vitro. Am J Physiol Gastrointest Liver Physiol 2007; 292: G923-G929 [PMID: 17170030]
43. Stattin P, Lukanova A, Biessy C, Söderberg S, Palmqvist R, Kaaks R, Olsson T, Jellum E. Obesity and colon cancer: does leptin provide a link? Int J Cancer 2004; 109: 149-152 [PMID: 14735482 DOI: 10.1002/ijc.11668]
44. Hursel R, Viechtbauer W, Westerterp-Plantenga MS. The effects of green tea on weight loss and weight maintenance: a meta-analysis. Int J Obes (Lond) 2009; 33: 956-961 [PMID: 19597519 DOI: 10.1038/ijo.2009.135]
45. Rains TM, Agarwal S, Maki KC. Antiobesity effects of green tea catechins: a mechanistic review. J Nutr Biochem 2011; 22: 1-7 [PMID: 21115335 DOI: 10.1016/j.jnutbio.2010.06.006]
46. Grove KA, Lambert JD. Laboratory, epidemiological, and human intervention studies show that tea (Camellia sinensis) may be useful in the prevention of obesity. J Nutr 2010; 140: 446-453 [PMID: 20089791 DOI: 10.3945/jn.109.115972]
47. Thielecke F, Boschmann M. The potential role of green tea catechins in the prevention of the metabolic syndrome - a review. Phytochemistry 2009; 70: 11-24 [PMID: 19147161 DOI: 10.1016/j.phytochem.2008.11.011]
48. Bose M, Lambert JD, Ju J, Reuhl KR, Shapses SA, Yang CS. The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr 2008; 138: 1677-1683 [PMID: 18716169]
49. Murase T, Nagasawa A, Suzuki J, Hase T, Tokimitsu I. Beneficial effects of tea catechins on diet-induced obesity: stimulation of lipid catabolism in the liver. Int J Obes Relat Metab Disord 2002; 26: 1459-1464 [PMID: 12439647 DOI: 10.1038/sj.ijo.0802141]
50. Ramadan G, El-Beih NM, Abd El-Ghffar EA. Modulatory effects of black v. green tea aqueous extract on hyperglycaemia, hyperlipidaemia and liver dysfunction in diabetic and obese rat models. Br J Nutr 2009; 102: 1611-1619 [PMID: 19825205 DOI: 10.1017/S000711450999208X]
51. Qin B, Polansky MM, Harry D, Anderson RA. Green tea polyphenols improve cardiac muscle mRNA and protein levels of signal pathways related to insulin and lipid metabolism and inflammation in insulin-resistant rats. Mol Nutr Food Res 2010; 54 Suppl 1: S14-S23 [PMID: 20112301 DOI: 10.1002/mnfr.200900306]
52. Li N, Sun Z, Han C, Chen J. The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proc Soc Exp Biol Med 1999; 220: 218-224 [PMID: 10202392]
53. Ahn WS, Yoo J, Huh SW, Kim CK, Lee JM, Namkoong SE, Bae SM, Lee IP. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J Cancer Prev 2003; 12: 383-390 [PMID: 14512803 DOI: 10.1097/01.cej.0000090186.08740.82]
54. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006; 66: 1234-1240 [PMID: 16424063]
55. Brausi M, Rizzi F, Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol 2008; 54: 472-473 [PMID: 18406041 DOI: 10.1016/j.eururo.2008.03.100]
56. Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H, Suganuma M, Fujiki H, Moriwaki H. Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev 2008; 17: 3020-3025 [PMID: 18990744 DOI: 10.1158/1055-9965.EPI-08-0528]
57. Shirakami Y, Shimizu M, Tsurumi H, Hara Y, Tanaka T, Moriwaki H. EGCG and Polyphenon E attenuate inflammation-related mouse colon carcinogenesis induced by AOM plus DDS. Mol Med Rep 2008; 1: 355-361 [PMID: 21479417]
58. Adachi S, Nagao T, Ingolfsson HI, Maxfield FR, Andersen OS, Kopelovich L, Weinstein IB. The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res 2007; 67: 6493-6501 [PMID: 17616711]
59. Adachi S, Nagao T, To S, Joe AK, Shimizu M, Matsushima-Nishiwaki R, Kozawa O, Moriwaki H, Maxfield FR, Weinstein IB. (-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells. Carcinogenesis 2008; 29: 1986-1993 [PMID: 18586691 DOI: 10.1093/carcin/bgn128]
60. Shirakami Y, Shimizu M, Adachi S, Sakai H, Nakagawa T, Yasuda Y, Tsurumi H, Hara Y, Moriwaki H. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci 2009; 100: 1957-1962 [PMID: 19558547 DOI: 10.1111/j.1349-7006.2009.01241.x]
61. Shirakami Y, Shimizu M, Moriwaki H. Cancer chemoprevention with green tea catechins: from bench to bed. Curr Drug Targets 2012; 13: 1842-1857 [PMID: 23140294]
62. Shimizu M, Deguchi A, Hara Y, Moriwaki H, Weinstein IB. EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. Biochem Biophys Res Commun 2005; 334: 947-953 [PMID: 16053920]
63. Shimizu M, Shirakami Y, Sakai H, Tatebe H, Nakagawa T, Hara Y, Weinstein IB, Moriwaki H. EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. Cancer Lett 2008; 262: 10-18 [PMID: 18164805 DOI: 10.1016/j.canlet.2007.11.026]
64. Chao A, Thun MJ, Connell CJ, McCullough ML, Jacobs EJ, Flanders WD, Rodriguez C, Sinha R, Calle EE. Meat consumption and risk of colorectal cancer. JAMA 2005; 293: 172-182 [PMID: 15644544 DOI: 10.293/2/172]
65. Forte A, De Sanctis R, Leonetti G, Manfredelli S, Urbano V, Bezzi M. Dietary chemoprevention of colorectal cancer. Ann Ital Chir 2008; 79: 261-267 [PMID: 19093628]
66. Lee GH, Proenca R, Montez JM, Carroll KM, Darvishzadeh JG, Lee JI, Friedman JM. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996; 379: 632-635 [PMID: 8628397 DOI: 10.1038/379632a0]
67. Hirose Y, Hata K, Kuno T, Yoshida K, Sakata K, Yamada Y, Tanaka T, Reddy BS, Mori H. Enhancement of development of azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice. Carcinogenesis 2004; 25: 821-825 [PMID: 14729596 DOI: 10.1093/carcin/bgh059]
68. Hayashi K, Suzuki R, Miyamoto S, Shin-Ichiroh Y, Kohno H, Sugie S, Takashima S, Tanaka T. Citrus auraptene suppresses azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db mice. Nutr Cancer 2007; 58: 75-84 [PMID: 17571970 DOI: 10.1080/01635580701308216]
69. Suzuki R, Kohno H, Yasui Y, Hata K, Sugie S, Miyamoto S, Sugawara K, Sumida T, Hirose Y, Tanaka T. Diet supplemented with citrus unshiu segment membrane suppresses chemically induced colonic preneoplastic lesions and fatty liver in male db/db mice. Int J Cancer 2007; 120: 252-258 [PMID: 17066427 DOI: 10.1002/ijc.22240]
70. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23: 363-398 [PMID: 12680238]
71. Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001; 172: 111-118 [PMID: 11566484]
72. Mukhopadhyay A, Banerjee S, Stafford LJ, Xia C, Liu M, Aggarwal BB. Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene 2002; 21: 8852-8861 [PMID: 12483537 DOI: 10.1038/sj.onc.1206048]
73. Shimizu M, Shirakami Y, Sakai H, Adachi S, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H. (-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev Res (Phila) 2008; 1: 298-304 [PMID: 19138973 DOI: 10.1158/1940-6207.CAPR-08-0045]
74. de Kloet AD, Krause EG, Woods SC. The renin angiotensin system and the metabolic syndrome. Physiol Behav 2010; 100: 525-534 [PMID: 20381510 DOI: 10.1016/j.physbeh.2010.03.018]
75. Smith GR, Missailidis S. Cancer, inflammation and the AT1 and AT2 receptors. J Inflamm (Lond) 2004; 1: 3 [PMID: 15813980]
76. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005; 5: 930-942 [PMID: 16341084]
77. Gauthaman K, Fong CY, Bongso A. Statins, stem cells, and cancer. J Cell Biochem 2009; 106: 975-983 [PMID: 19224538 DOI: 10.1002/jcb.22092]
78. Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC, Song IS. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer 2008; 123: 951-957 [PMID: 18521906 DOI: 10.1002/ijc.23593]
79. Yasui Y, Suzuki R, Miyamoto S, Tsukamoto T, Sugie S, Kohno H, Tanaka T. A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis. Int J Cancer 2007; 121: 2331-2339 [PMID: 17657716 DOI: 10.1002/ijc.22976]
80. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G. Statins and the risk of colorectal cancer. N Engl J Med 2005; 352: 2184-2192 [PMID: 15917383 DOI: 10.352/21/2184]
81. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, Kato M, Nakamura T, Higuchi K, Nishiguchi S, Kumada H, Ohashi Y. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006; 35: 204-214 [PMID: 16737844]